Active substances
Polyethylene glycol + Propylene glycol
- SFDA 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| SYSTANE LUBRICANT EYE DROPS | 0.4,0.3 %,% | Eye drops · Ophthalmic use | 1 Dropper Container | SAR 31.05 | Generic · OTC | ALCON LABORATORIES | Valid |
| SYSTANE ULTRA UD LUBRICANT EYE DROPS | 0.4,0.3 %,% | Eye drops · Ophthalmic use | 30 Single Dose Container | SAR 47.80 | NCE · OTC | ALCON LABORATORIES | Valid |
Indications — CHI Daman Drug Formulary
ALLERGIC CONJUCTIVITIS (AC); ANESTHESIA-SUPPORTIVE AGENTS/ EYE DRYNESS IN PATIENTS RECEIVING CONTINUOUS INFUSIONS OF NEUROMUSCULAR BLOCKERS.; BELL'S PALSY; OCULAR ROSACEA; SJOGREN'S SYNDROME; VIRAL CONJUNCTIVITS, HERPESVIRAL KERATITIS, HERPESVIRAL CONJUNCTIVITIS, VARICELLA KERATITIS, ZOSTER CONJUNCTIVITIS, ZOSTER KERATITIS, MEASLES KERATITIS AND KERATOCONJUNCTIVITIS, VIRAL CONJUNCTIVITIS, KERATITIS
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.